Lutetium-177 Dotatate-Induced Hemolytic Anemia and Myelodysplastic Syndrome

Samer Alkassis 1, Mohammed Ali 1, Abdalaziz M. Awadelkarim 2, Eltaib Saad 1, Adnan Halboni 1, 4, Rashid Alhusaini 1, Saivaishnavi Kamatham 1, Isha Idris 5

1. Internal Medicine, Wayne State University Detroit Medical Center, Detroit, USA 2. Internal Medicine, Wayne State University Detroit Medical Center, Detroit, USA 3. Internal Medicine, AMITA Saint Francis Hospital, Evanston, USA 4. Internal Medicine, Wayne State, Detroit, USA 5. Pediatrics, WoodHull Medical Center, New York, USA

Corresponding author: Isha Idris, idrisi@nychhc.org

Abstract

Lutetium-177 (177Lu) dotatate is a type of peptide receptor radioligand therapy (PRRT) using radiolabeled somatostatin to patients with progressive somatostatin receptor-positive gastrointestinal neuroendocrine tumors. While cases of therapy-related myeloid neoplasms (t-MN) have been described as a consequence of 177Lu dotatate, there are no reports of hemolytic anemia associated with therapy. We present a case of a 68-year-old woman with metastatic low-grade neuroendocrine tumor who presented four weeks after the second dose of 177Lu dotatate with progressive fatigue and dyspnea. Laboratory workup was remarkable for hemolytic anemia. Lutetium-177 dotatate-induced hemolysis was suspected after ruling out other causes. Corticosteroid treatment was initiated with improvement in hemoglobin, and dose-reduced PRRT was planned upon discharge. Six months into the treatment course of 177Lu dotatate, macrocytic anemia was noticed on routine follow-up with normal vitamin B12 and folic acid levels. A bone marrow biopsy was done, revealing myelodysplastic syndrome (MDS) features. Given the temporal relationship between drug introduction and the objective findings, early-onset 177Lu dotatate-induced MDS was diagnosed with a plan for close hematologic follow-up. Myelodysplastic syndrome should be suspected when megaloblastic anemia develops in patients with previous 177Lu dotatate therapy. The latency period between initial treatment and MDS diagnosis reported in the literature ranges between 15 months to seven years. While cases of therapy-related myeloid neoplasms (t-MN) have been described, there are no reports of hemolytic anemia associated with therapy. 

Introduction

Lutetium-177 (177Lu) dotatate, commonly known as Lutathera®, is a peptide receptor radioligand therapy (PRRT) using radiolabeled somatostatin. On January 26, 2018, the Food and Drug Administration (FDA) approved its use for patients with somatostatin receptor-positive gastrointestinal neuroendocrine tumors (GEP-NETs), who have progressed during somatostatin analog therapy [1]. Lutetium is a lower energy beta-emitting radionuclide. Exposure to high doses of radiation occurs by selectively binding to tumor cells with limited toxicity on normal tissue [2]. Despite this fact, hematologic adverse events have been commonly reported - myelosuppression was reported as a side effect during drug development. However, persistent hematologic dysfunction, defined as myelodysplastic syndrome (MDS), is uncommon [3-5]. The latency period between initial treatment with 177Lu dotatate and MDS diagnosis ranges between 15 months to seven years. While cases of therapy-related myeloid neoplasms (t-MN) have been described in the literature, there are no reports of hemolytic anemia. Herein, we present a case of 177Lu dotatate-induced hemolysis and MDS that developed as an early and delayed adverse effect of therapy, respectively.

Case Presentation

A 68-year-old woman with a past medical history of essential hypertension (amlodipine 10 mg) and cholelithiasis (status post cholecystectomy) was found to have a rectal polyp during a routine colonoscopy with a biopsy revealing a low-grade neuroendocrine tumor. Endo-mucosal resection of the polyp was attempted a few months later. However, invasion of the muscularis propria was noted. Therefore, the procedure was aborted. A CT scan of the abdomen and pelvis was done for further evaluation showing a large complex mass in the left lobe of the liver. This was followed by an MRI of the bdomen, which showed a cystic liver lesion with rim enhancement, and multiple additional smaller lesions (Figure 1). She was started on

How to cite this article

Alkassis S, Ali M, Awadelkarim A M, et al. (February 19, 2022) Lutetium-177 Dotatate-Induced Hemolytic Anemia and Myelodysplastic Syndrome. Cureus 14(2): e22392. DOI 10.7759/cureus.22392
octreotide 20 mg every four weeks. However, a repeat CT scan showed disease progression after five months of therapy. The dose of octreotide was increased to 30 mg, and she was referred to our institution for further evaluation. Given the lack of response to octreotide, she was deemed a candidate for palliative \textsuperscript{177}Lu dotatate, with a plan for a total course of four doses to be administered every eight weeks. The first dose was tolerated without complications. However, she was admitted to the hospital four weeks after the second dose with malaise, progressive fatigue, and dyspnea.

![Image of MRI of the abdomen showing an intrinsic T1 hyperintense lesion consistent with a large 14.9 x 14.0 cm complex necrotic mass in the left hepatic lobe (blue arrow), with innumerable small metastatic lesions throughout the liver parenchyma (blue arrowheads).](image)

**FIGURE 1:** MRI of the abdomen showing an intrinsic T1 hyperintense lesion consistent with a large 14.9 x 14.0 cm complex necrotic mass in the left hepatic lobe (blue arrow), with innumerable small metastatic lesions throughout the liver parenchyma (blue arrowheads).

Laboratory workup on presentation revealed normocytic anemia (6.2 g/dL from a baseline of 11 g/dL) and grade II thrombocytopenia. Further hematologic workup was significant for low haptoglobin, high lactate dehydrogenase (LDH), and indirect hyperbilirubinemia. Refer to Table \ref{table:hematologic_indices} for complete hematologic indices with their reference ranges. Peripheral blood smear revealed anisocytosis, burr cells, and very few schistocytes. Hemolytic workup, including direct antiglobulin test; a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS 13); cold agglutinin; and viral panel screening, was negative. The patient required one unit of packed red blood cell transfusion. Lutetium-\textsuperscript{177} dotatate-induced hemolysis was suspected after consultation with the hematology team. The patient received a six-day course of prednisone 80 mg daily with improvement in hemoglobin close to her baseline. However, the plan upon discharge was to continue with dose-reduced PRRT; she received two additional doses of \textsuperscript{177}Lu dotatate to complete four doses.
| Laboratory test                              | Patient's result | Reference range   |
|---------------------------------------------|------------------|-------------------|
| White Cells Count (WCC)                     | 6.5 k/ L         | 3.3-10.7 k/ L     |
| Absolute Neutrophil Count                   | 4.7 k/ L         | 1.6-7.2 k/ L      |
| Hemoglobin                                  | 6.2 g/dl (Baseline 11 g/dl) | 12.1-15.0 g/dL    |
| Hematocrit                                  | 19.9%            | 34.4-44.2%        |
| Mean Corpuscular Volume (MCV)               | 96 fl            | 80-100 fl         |
| Absolute reticulocyte count                 | 123,500/ L       | 20,000-100,000/ L |
| Reticulocyte%                               | 5.5%             | 0.5-2.0%          |
| Platelets                                   | 99 k/ L          | 150-400 k/ L      |
| Mean Platelets Volume                       | 10.1 fl          | 7-12 fl           |
| Total Bilirubin                             | 3.47 mg/dL       | <1.5 mg/dL        |
| Indirect Bilirubin                          | 1.52 mg/dL       | 0.0-0.80 mg/dL    |
| Direct Bilirubin                            | 1.95 mg/dL       | 0.03-0.18 mg/dL   |
| Aspartate Transference (AST)                | 20 units/L       | 7-52 units/L      |
| Alanine Aminotransferase (ALT)              | 39 units/L       | 13-39 units/L     |
| Alkaline Phosphatase (ALP)                  | 170 units/L      | 50-142 units/L    |
| Lactate Dehydrogenase (LDH)                 | 319 unit/L       | 140-217 unit/L    |
| Haptoglobin                                 | <30 mg/dL        | 9.0-25.0 mg/dL    |
| Fibrin Monomers                             | negative         | negative          |
| Fibrinogen                                  | 378 mg/dl        | 186-466 mg/dl     |
| International Normalized Ratio (INR)        | 1.03             | 0.90 -1.13        |
| Activated Partial Thromboplastin Time (APTT) | 27.6             | 23.1-33.1         |
| Cold Agglutinins                            | < 1:32           | < 1:32            |
| ADAMTS13                                    | 69%              | 75 – 117%         |

**TABLE 1: Laboratory workup at the time of presentation with their reference ranges**

ADAMTS13: A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13

Five weeks after the last dose of PRRT, macrocytic anemia was demonstrated on regular follow-up with persistent thrombocytopenia (Figure 2). Vitamin B12 and folic acid were within normal limits. Repeat peripheral smear showed anisopoikilocytosis consisting of ovalocytes, acanthocytes, burr cells. Further investigation with 13bone marrow biopsy was obtained, revealing dyserythropoiesis with mild dysmegakaryopoiesis suggestive of MDS. Cytogenetics revealed a uniform pattern of a normal female karyotype with no consistent numerical or structural clonal aberration. The fluorescence in situ hybridization (FISH) panel was also negative. Given the temporal relationship between drug introduction and the objective findings, 111Lu dotatate-induced MDS was diagnosed. The plan was to continue to follow up in the hematology clinic and to check blood count regularly.
FIGURE 2: Graph depicting hemoglobin [g/dL], mean corpuscular volume (MCV) [fL], and platelets [k/μL] during and after treatment with lutetium-177 dotatate

Discussion

Lutetium-177 dotatate is a combination of the radionuclide $^{177}\text{Lu}$ with the somatostatin analog DOTA-TATE. Single- and double-stranded DNA breaks are induced by ionizing radiation specifically to somatostatin-receptor-positive tumor cells, leading to tumor cell death [6]. As a result of DNA breaks, errors in the repair mechanism occur and contribute to genetic mutations [4]. This also could be the potential pathogenesis of $^{177}\text{Lu}$ dotatate-induced hematologic toxicity.

The incidence of therapy-related myeloid neoplasms (t-MN), including MDS, acute leukemia, and myeloproliferative disorder, has been reported to be 2.61% in a recent systematic review [7]. In a clinical trial involving 807 patients with neuroendocrine neoplasm treated with PRRT, MDS and acute myeloid leukemia (AML) occurred in 2.35% and 1.1% of patients, respectively [4]. Another study of 274 patients who underwent PRRT with $^{177}\text{Lu}$ for gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) showed hematopoietic neoplasm in 2.9% of the patients, and bone marrow failure in 1.1% who developed bone marrow failure characterized by cytopenia. In a small study in France, the incidence of MDS/AML was high (20%) in patients with GEP-NETs treated with PRRT following treatment with alkylating chemotherapy [8].

As demonstrated above, a comprehensive literature review yields multiple reports that describe t-MN as a consequence of PRRT. Myelodysplastic syndrome should be suspected when megaloblastic anemia develops in patients with previous $^{177}\text{Lu}$ dotatate therapy. The latency period between initial treatment and MDS diagnosis reported in the literature ranges between 15 months to seven years [3]. However, what is unique about our case is the early onset of MDS (six months into treatment course) and the development of hemolytic anemia after administration of PRRT.

The brisk response to corticosteroids and the return of hemoglobin to baseline values are strongly supportive of immune-mediated hemolytic anemia. The absence of laboratory evidence of other causes of hemolysis increased clinical suspicion of PRRT as the etiology of the observed hemolysis. However, Coombs-negative autoimmune hemolytic anemia has been described in association with MDS. Additionally, the lack of platelet count response to steroids hints that thrombocytopenia was likely not immune-mediated and could be explained by either bone marrow toxicity of PRRT therapy or secondary to an underlying MDS that was undiagnosed at the time of presentation [6-8]. However, the later absence of significant anemia at the time of MDS diagnosis, the relatively low mean platelet volume, and the marginally elevated mean corpuscular volume (MCV) on presentation don’t support MDS as the underlying etiology for the immune-mediated hemolytic anemia observed in our patient.

To our knowledge, $^{177}\text{Lu}$ dotatate-induced hemolysis has not been described before in the...
literature. Furthermore, the nature of this adverse event suggests the presence of other mechanisms of PRRP toxicity besides DNA breaks, genetic mutations, and myelosuppression [1,2]. An immune-mediated component likely plays a role given the improvement of hemoglobin after corticosteroid administration and the return of hemoglobin to baseline levels at the time of MDS diagnosis.

Conclusions

Myelodysplastic syndrome should be suspected when megaloblastic anemia develops in patients with previous 177Lu dotatate therapy. Immune-mediated hemolytic anemia is a potential adverse effect of PRRT therapy. Further investigations are needed to identify the frequency of such adverse events and the pathophysiology of their occurrence.

Additional Information

Disclosures

Human subjects: All authors have confirmed that this study did not involve human participants or tissue.

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Strosberg J, El-Haddad G, Wolin E, et al.: Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017, 376:125-135. 10.1056/NEJMoa1607427
2. Vallathol DH, Ali AZ, Alapati N, Manasa N, Vasanth P, Digumarti R: Lutetium 177 dotate induced acute myeloid leukemia. Leuk Lymphoma. 2020, 61:3263-3265. 10.1080/10428194.2020.1795158
3. Bergama H, van Lom K, Raaijmakers MH, et al.: Persistent hematologic dysfunction after peptide receptor radionuclide therapy with 177Lu-DOTATATE: incidence, course, and predicting factors in patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2018, 59:452-458. 10.2967/jnnumed.117.189712
4. Bodei L, Kidd M, Paganelli G, et al.: Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015, 42:5-19. 10.1007/s00259-014-2899-5
5. Sabet A, Ezziddin K, Pape UF, et al.: Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med. 2015, 54:1857-1861. 10.2967/jnnumed.112.119547
6. Henrich U, Kopka K: Lutathera®: the first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy. Pharmaceuticals (Basel). 2019, 12:114. 10.3390/ph12030114
7. Sonhol MB, Halfdanarson TR, Hilal T: Assessment of therapy-related myeloid neoplasms in patients with neuroendocrine tumors after peptide receptor radionuclide therapy: a systematic review. JAMA Oncol. 2020, 6:1086-1092. 10.1001/jamaoncol.2020.0578
8. Brieau B, Hentic O, Lebtahi R, et al.: High risk of myelodysplastic syndrome and acute myeloid leukaemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy. Endocr Relat Cancer. 2016, 23:L17-L23. 10.1530/ERC-15-0545